PHOENIX--(BUSINESS WIRE)--April 3, 2003--Vital Living Inc. (OTCBB:VTLV), the Physician Nutraceutical Company(SM) today announced that it has entered into an agreement with Healthcare Financial Services, Inc. ("HFS") of Phoenix, AZ to market and distribute Essentum(TM) and Essentum N.P. to doctors and practitioners.
The contract includes dispensing the Company's products in Portland, Seattle, "Bay Area" of California, Orange County, California, Chicago and Atlanta. Sales reps would be dedicated to each of these cities by HFS on behalf of Vital Living.
Vital Living will provide training and materials for the sales reps. Specific product training commenced in Vital Living's Phoenix office on March 18, 2003, and initiation of sales in the field are anticipated to begin immediately.
HFS' sales force will be compensated on a commission basis, with some costs of marketing being covered by Vital Living.
According to Stuart A. Benson, Executive Vice-President of Vital Living, "We are extremely excited about launching our national sales initiative. We have numerous practitioners that have been contacting the Company to learn more about heart supplements, and this will allow the Company to expand its distribution into the many professional practitioners who would be interested in prescribing this for their patients."
Javier Ledesma of Healthcare Financial Services, Inc. stated, "We are very pleased to be able to offer this outstanding new medical food supplement for our practicing physicians. We have been looking for an effective cardiac product that our physicians can offer to mitigate the diagnosed risk of heart disease for their patients. This new line of products should gain immediate acceptance with our many medical accounts."
About Healthcare Financial Services, Inc.
Healthcare Financial Services, Inc. currently has a nationwide sales force that sells products and services into doctors' offices throughout the United States. Currently, the firm services 500 major medical institutions, hospitals, surgery centers and individual physician's offices and medical accounts in 49 states.
About Vital Living
Vital Living develops and markets evidence-based nutraceuticals formulated by physicians for distribution through physicians. The Company is developing and testing nutraceuticals in collaboration with leading medical experts based on the best available scientific evidence.
Vital Living's nutraceuticals are designed to be incorporated by physicians into a standard physician/patient program, supported by a specially designed compliance regimen. The Company's initial area of focus is cardiovascular health, the leading health concern in America affecting 60 million consumers. Essentum(TM) is currently being endorsed and prescribed at the Arizona Heart Institute as part of a comprehensive cardiovascular health program as well as other medical facilities. Its cardiovascular health supplement products are also prescribed for patients in Canyon Ranch Health Resort's leading Wellness and Prevention programs in Tucson, AZ.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the company's product development partners, the ability of the company to meet its financial projections and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.